PUBLISHER: Grand View Research | PRODUCT CODE: 1790296
PUBLISHER: Grand View Research | PRODUCT CODE: 1790296
Veterinary Anti-infectives Market Summary
The global veterinary anti-infectives market was estimated at USD 8.26 billion in 2024 and is projected to reach USD 14.37 billion by 2033, growing at a CAGR of 6.5% from 2025 to 2033. Key factors expected to drive the market include the rise in animal infectious diseases, developing research initiatives, a boost to prudent antibiotic use, increasing regulatory approvals, and growing applications of Artificial Intelligence (AI).
One of the foremost drivers is the growing integration of artificial intelligence (AI) in veterinary practices. Educational institutions, animal welfare bodies, and commercial players are adopting AI to streamline clinical decision-making, assist in early disease detection, identify treatment gaps, and even accelerate veterinary drug discovery. AI also offers potential for predictive modeling in outbreak surveillance, helping to rationalize anti-infective use amid rising concerns of antimicrobial resistance (AMR).
Another critical factor is the increasing global prevalence of infectious diseases in companion and livestock animals. For example, India-a leading dairy-producing country-witnessed a severe outbreak of Lumpy Skin Disease in 2023, which infected nearly 2.95 million cattle and resulted in over 155,000 deaths across 15 states. Similarly, in the U.S., one of the world's top beef producers, a recent outbreak of highly pathogenic avian influenza (HPAI) among cattle saw over 250 beef samples from 38 states testing positive as of May 2024. South Africa also faced a 30% drop in egg production and had to cull over a million poultry in 2023 due to HPAI. These disease outbreaks are directly escalating the demand for effective anti-infective therapies.
Rising antimicrobial resistance (AMR) is also shaping the market, prompting stricter regulatory surveillance. In June 2025, India's Central Drugs Standard Control Organisation (CDSCO) launched a nationwide initiative to monitor antibiotic use in livestock. It established inter-agency collaborations and mandated AMU (antimicrobial use) data reporting to combat misuse and overuse of antibiotics, which can drive the development and adoption of newer, more targeted anti-infectives.
Intensive R&D and industry collaborations support these regulatory developments. In March 2024, Zoetis partnered with Blacksmith Medicines to develop novel antibiotics to circumvent bacterial resistance by selectively targeting drug-resistant strains. Likewise, discoveries such as bird flu's zoonotic shift to cattle-uncovered by a veterinarian in Texas-open new avenues for therapeutic innovation in livestock disease management.
Additionally, the growth of generic and value-added veterinary medicines is expanding market accessibility. The 2024 European Market Study by Access VetMed revealed that generics account for around 50% of all veterinary product authorizations, with significant traction in anti-infectives and antiparasitics. Despite regulatory burdens like EU Regulation 2019/6, especially for SMEs, the sector remains growing, particularly for companion animal products and alternative administration routes.
Overall, the rise in infectious disease outbreaks, regulatory tightening on antimicrobial use, technological innovations like AI, and increased investment in R&D and generics significantly propel the veterinary anti-infectives market. These forces are expected to meet current treatment demands and ensure veterinary antimicrobial therapy's long-term sustainability and efficacy.
Global Veterinary Anti-infectives Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global veterinary anti-infectives market report based on animal type, product, route of administration, type, distribution channel & region.